Tecentriq® (atezolizumab), Avastin® (bevacizumab) – New indication
May 29, 2020 - Genentech announced the FDA approval of Tecentriq (atezolizumab), in combination with bevacizumab (eg, Avastin®), is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Top